Bridgeway Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Bridgeway Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-65,000	Closed	-$598K	–	1411
2017 Q1	$598K	Hold	65,000	–	–	0.01%	1000
2016 Q4	$677K	Hold	65,000	–	–	0.01%	956
2016 Q3	$588K	Hold	65,000	–	–	0.01%	1019
2016 Q2	$486K	Sell	65,000 -16,250	-20%	-$142K	0.01%	1059
2016 Q1	$732K	Sell	81,250 -15,400	-16%	-$125K	0.01%	900
2015 Q4	$1.25M	Hold	96,650	–	–	0.02%	658
2015 Q3	$934K	Hold	96,650	–	–	0.02%	772
2015 Q2	$995K	Buy	96,650 +65,000	+205%	+$555K	0.02%	790
2015 Q1	$352K	Buy	+31,650	New	+$337K	0.01%	1210

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's AKBA Position: Q2 2017 in Review

Bridgeway Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2017, closing a stake of 65,000 shares — an estimated $598K sold.

Bridgeway Capital Management first reported a position in AKBA in Q1 2015 and held it in 9 quarters. The position peaked at $1.25M in Q4 2015. 118 funds tracked by Wall St. Rank hold AKBA as of Q2 2017.

Bridgeway Capital Management reported no remaining Akebia Therapeutics position as of Q2 2017 after selling out during the quarter.
Bridgeway Capital Management sold 65,000 Akebia Therapeutics shares in Q2 2017, an estimated $598K.
Bridgeway Capital Management first reported a position in Akebia Therapeutics in Q1 2015 and held it in 9 quarters.
Bridgeway Capital Management's Akebia Therapeutics position peaked at $1.25M in Q4 2015.
118 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2017.

Based on Bridgeway Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.